DUBLIN–(BUSINESS WIRE)–The “Diabetes
Therapies Global Market Opportunities And Strategies To 2023”
report has been added to ResearchAndMarkets.com’s
offering.
This report describes and evaluates the global market for diabetic
therapies. It covers two five-year periods, 2014 to 2018, termed the
historic period, and 2018 through 2023, the forecast period.
The diabetic therapies market reached a value of nearly $50.7 billion in
2018 and is expected to grow at a compound annual growth rate (CAGR) of
6.4% to nearly $69.3 billion by 2023.
Factors such as rising disposable income and increasing spending on
healthcare in emerging markets, increasing grants from government
agencies for diabetic therapies drugs research and development and
rising awareness of this disease globally are contributing to the growth
of the market. Potential threats include pressure from regulators on
diabetic drugs manufacturers to offer diabetic drugs at affordable
prices, drug patent expiry, high drug discovery and development costs
and rising trade protectionism.
North America is the largest region in the diabetic therapies market,
accounting for 39.2% of the global market in 2018. It was followed by
Asia Pacific and Western Europe. Going forward, the fastest growth in
the diabetic therapies market is predicted for Asia Pacific, where it is
expected at grow at a CAGR of 12.3%, followed by Africa at a CAGR of
6.9%. The largest country in terms of value in the diabetic therapies
market is the USA. China and India are forecast to have the fastest
growth at CAGRs of 16.7% and 13.3% respectively.
The injectable drugs segment accounted for the largest share of the
diabetic therapies market in 2018 at $32.3 billion. This large share in
the market was due to the prices of injectables being higher than for
oral drugs. The highest growth is also projected to come from the
injectables segment, which is forecast to grow at a CAGR of 6.9%. Major
factors for this growth include increasing access to injectables in
developing and some underdeveloped countries. Increasing awareness of
diabetes also contribute to this growth.
The market for diabetic therapies is concentrated. Major players in the
market are Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck &
Company, Inc., C.H. Boehringer Sohn AG & Ko. KG and others. Merger and
acquisition activities in the diabetes therapies market have been at a
high level in the last three years. Major deals include those completed
by Takeda Pharmaceutical Company Ltd., AstraZeneca plc, PHC Holdings
Corporation, and Eli Lilly and Company,
Major opportunities in the diabetic therapies market will arise in the
injectables segment of the market, which will add $12.75 billion in
annual sales by 2023, equivalent to 68% of all the global market growth
in $ terms. The USA, which will add $3.43 billion of annual sales by
2023, is the country offering the most significant market opportunities.
Strategies suggested by the author’s analysis of diabetic therapy market
trends include the development of new drugs for diabetes-associated
comorbidities. Business strategies adopted by major companies in the
diabetic therapies market include investing in expanding manufacturing
operations, improving infrastructure and in acquisitions and mergers to
strengthen their product and service offerings.
The report covers the following chapters
-
Market Characteristics – The market characteristics section of the
report defines and explains the diabetes therapies market. This
chapter includes different goods and services covered in the report,
basic definitions and market supply chain analysis. -
Global Market Size And Growth – This section contains the global
historic (2014-2018) and forecast (2018-2023) market value, and
drivers and restraints that support and control the growth of the
market in the historic and forecast period. -
Trends And Strategies – This chapter includes some of the major trends
shaping the global diabetes therapies market by segment. This section
highlights likely future developments in the market and suggests
approaches companies can take to exploit these opportunities. -
Global Market Segmentation – This section contains global segmentation
of the diabetes therapies market for 2018. Segmentation types include
by region and by country segmentation of the diabetes therapies market. -
Global Macro Comparison – The global diabetes therapies market
comparison with macro-economic factors gives the diabetes therapies
market size, percentage of GDP, and average diabetes therapies market
expenditure. -
Region/Country Market Size And Growth – This section contains the
region’s market size (2018), historic (2014-2018) and forecast
(2018-2023) market value, and growth. This report includes information
on all the regions (Asia Pacific, Western Europe, Eastern Europe,
North America, South America, Middle East and Africa) and major
countries within each region. -
Competitive Landscape – This section covers details on the competitive
landscape of the global diabetes therapies market, estimated market
shares and company profiles for the leading players. -
Key Mergers And Acquisitions – This chapter gives the information on
recent mergers and acquisitions in the market covered in the report.
This section gives key financial details of mergers and acquisitions
which have shaped the market in recent years. -
Opportunities And Strategies – This section gives information on
growth opportunities across countries, segments and strategies to be
followed in those markets. It gives an understanding of where there is
significant business to be gained by competitors in the next five
years.
Reasons to Purchase
-
Outperform competitors using accurate up to date demand-side dynamics
information - Identify growth segments for investment
-
Facilitate decision making on the basis of historic and forecast data
and the drivers and restraints on the market -
Create regional and country strategies on the basis of local data and
analysis - Stay abreast of the latest customer and market research findings
- Benchmark performance against key competitors
- Develop strategies based on likely future developments
-
Utilize the relationships between key data sets for superior
strategizing -
Suitable for supporting your internal and external presentations with
reliable high quality data and analysis - Gain a global perspective on the development of the market
Companies Mentioned
- Allergan
- AstraZeneca
- Bayer
- Biocon Limited
- Bristol-Myers Squibb
- C.H. Boehringer Sohn AG & KO. KG
- Eli Lilly
- Glycostasis
- Johnson & Johnson
- Merck & Company Inc.
- Novo Nordisk A/S
- PHC Holdings
- Sanofi S.A.
- Shire
- Sun Pharmaceutical Industries Limited
- Takeda Pharmaceutical
- Teva
- ZS Pharma
For more information about this report visit https://www.researchandmarkets.com/research/3bnhxn/69_billion?w=4
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrinology